Market Overview:
The global cancer drug therapy market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing incidence of cancer, rising demand for novel therapies, and technological advancements in the field of oncology. The global cancer drug therapy market is segmented by type into targeted therapy, chemotherapy, and immunotherapy. The targeted therapy segment dominates the market owing to its high efficacy and safety as compared to other treatment modalities. By application, the angiogenesis inhibitors segment accounts for the largest share of the market due to their ability to inhibit tumor growth by blocking blood vessel formation in tumors. The mTOR inhibitors segment is projected grow at a highest CAGR during forecast period owing their ability block proteins that promote cell growth and division (proliferation). Geographically, North America dominates the global cancer drug therapy market followed by Europe due high prevalence of cancer cases in these regions coupled with increasing adoption rates for novel therapies such as immunotherapy drugs.
Product Definition:
Cancer Drug Therapy is the medical treatment of cancer. The main goal of cancer drug therapy is to kill or stop the growth of cancer cells while doing as little harm as possible to normal cells.
Targeted Therapy:
Targeted therapy is a branch of pharmacology that concentrates on specific molecular targets for drug design. The main aim of targeted therapy is to treat the root cause of disease by targeting only those affected cells with high precision.
The major factors driving the growth factor in cancer drug therapy market are increasing prevalence and mortality rate due to cancer, growing demand for targeted therapies, technological advancements pertaining to genetic sequencing and proteomics coupled with rising R&D activities pertaining to oncology drugs.
Chemotherapy:
Chemotherapy is the use of drugs or chemical substances to treat cancer. Chemotherapy can be used with radiation therapy, biotherapy, and immunotherapy. The most common types of chemotherapies are alkylating agents (such as busulfan), cytotoxic agents (such as carmustine), antimetabolites (such as 5-fluorouracil), plant derivatives (such as vincristine) and non-specific drugs.
Global chemotherapy.
Application Insights:
Angiogenesis inhibitors were the most prominent cancer treatment drugs in 2017. These are used for the treatment of various angiogenic tumor types, such as neuroendocrine tumors, breast carcinoma and others. The growing number of approvals for these drugs is a key factor contributing to their large share. For instance, bezlotoxumab by Biogen Inc., which was approved by U.S FDA in 2018 is an angiogenesis inhibitor that targets vascular endothelial growth factor (VEGF) produced by tumor cells and macrophages which leads to inhibition of tumor blood supply and growth inhibition in vitro &in vivo studies.
The mTOR inhibitors segment held a significant share owing to their ability to treat cancers with minimal side effects compared with other conventional chemotherapy drugs or radiation therapy options available for treating these diseases. mTOR stands for mammalian Target Of Rapamycin which is an important signaling pathway involved in cell proliferation & survival as well as drug resistance against chemotherapy & radiotherapy among others.
Regional Analysis:
North America dominated the global cancer drug therapy market in 2017. Key factors contributing to its growth are the presence of key players, availability of effective drugs, high R&D investment by companies and government support for early diagnosis. For instance, in September 2018, Pfizer Inc. invested USD X million over a period of three years to establish a research center in Israel focused on immunotherapy discovery and development programs targeting advanced cancers (breast cancer). The company also established an office in Ireland focusing on new chemical entities for pipeline programs targeting solid tumors such as neuroendocrine tumors and breast cancer.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the global cancer drug therapy market. According to a study by the World Health Organization (WHO), an estimated 14 million new cases of cancer were diagnosed in 2012, and this number is expected to rise to 24 million by 2035. This growing prevalence of cancer is primarily attributed to the aging population and lifestyle changes.
- Rising demand for targeted therapies: The demand for targeted therapies is another key growth driver for the global cancer drug therapy market. Targeted therapies are drugs that are designed to specifically attack tumor cells, while sparing healthy cells. They offer several advantages over traditional chemotherapy regimens, such as improved efficacy and reduced toxicity levels. As a result, their use has been increasing rapidly in recent years, fueling market growth.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Drug Therapy Market Research Report
By Type
Targeted Therapy, Chemotherapy, Immunotherapy
By Application
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)
By Companies
Amgen / Allergan, Argos Therapeutics, AstraZeneca, Aveo Pharmaceuticals, Bayer, Exelixis, Incyte, Merck, Roche, Bristol-Myers Squibb, Amgen / Allergan, Exelixis, Genentech (Roche), Novartis, Pfizer, Prometheus Labs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
190
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Drug Therapy Market Report Segments:
The global Cancer Drug Therapy market is segmented on the basis of:
Types
Targeted Therapy, Chemotherapy, Immunotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen / Allergan
- Argos Therapeutics
- AstraZeneca
- Aveo Pharmaceuticals
- Bayer
- Exelixis
- Incyte
- Merck
- Roche
- Bristol-Myers Squibb
- Amgen / Allergan
- Exelixis
- Genentech (Roche)
- Novartis
- Pfizer
- Prometheus Labs
Highlights of The Cancer Drug Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- By Application:
- Angiogenesis Inhibitors
- mTOR Inhibitors
- Monoclonal Antibodies
- Cytokine Immunotherapy (IL-2)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Drug Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer drug therapy is the use of medications to treat cancer. These medications can be used alone or in combination with other treatments.
Some of the major companies in the cancer drug therapy market are Amgen / Allergan, Argos Therapeutics, AstraZeneca, Aveo Pharmaceuticals, Bayer, Exelixis, Incyte, Merck, Roche, Bristol-Myers Squibb, Amgen / Allergan, Exelixis, Genentech (Roche), Novartis, Pfizer, Prometheus Labs.
The cancer drug therapy market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Drug Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Drug Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Drug Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Drug Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Drug Therapy Market Size & Forecast, 2020-2028
4.5.1 Cancer Drug Therapy Market Size and Y-o-Y Growth
4.5.2 Cancer Drug Therapy Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Targeted Therapy
5.2.2 Chemotherapy
5.2.3 Immunotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Angiogenesis Inhibitors
6.2.2 mTOR Inhibitors
6.2.3 Monoclonal Antibodies
6.2.4 Cytokine Immunotherapy (IL-2)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Drug Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Drug Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Targeted Therapy
9.6.2 Chemotherapy
9.6.3 Immunotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Angiogenesis Inhibitors
9.10.2 mTOR Inhibitors
9.10.3 Monoclonal Antibodies
9.10.4 Cytokine Immunotherapy (IL-2)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Targeted Therapy
10.6.2 Chemotherapy
10.6.3 Immunotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Angiogenesis Inhibitors
10.10.2 mTOR Inhibitors
10.10.3 Monoclonal Antibodies
10.10.4 Cytokine Immunotherapy (IL-2)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Targeted Therapy
11.6.2 Chemotherapy
11.6.3 Immunotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Angiogenesis Inhibitors
11.10.2 mTOR Inhibitors
11.10.3 Monoclonal Antibodies
11.10.4 Cytokine Immunotherapy (IL-2)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Targeted Therapy
12.6.2 Chemotherapy
12.6.3 Immunotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Angiogenesis Inhibitors
12.10.2 mTOR Inhibitors
12.10.3 Monoclonal Antibodies
12.10.4 Cytokine Immunotherapy (IL-2)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Targeted Therapy
13.6.2 Chemotherapy
13.6.3 Immunotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Angiogenesis Inhibitors
13.10.2 mTOR Inhibitors
13.10.3 Monoclonal Antibodies
13.10.4 Cytokine Immunotherapy (IL-2)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Drug Therapy Market: Competitive Dashboard
14.2 Global Cancer Drug Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen / Allergan
14.3.2 Argos Therapeutics
14.3.3 AstraZeneca
14.3.4 Aveo Pharmaceuticals
14.3.5 Bayer
14.3.6 Exelixis
14.3.7 Incyte
14.3.8 Merck
14.3.9 Roche
14.3.10 Bristol-Myers Squibb
14.3.11 Amgen / Allergan
14.3.12 Exelixis
14.3.13 Genentech (Roche)
14.3.14 Novartis
14.3.15 Pfizer
14.3.16 Prometheus Labs
